抗生素与晚期肾细胞癌及非小细胞肺癌免疫检查点抑制剂疗效负相关
该研究在两家学术机构回顾了晚期肾细胞癌(RCC)和非小细胞肺癌(NSCLC)患者,比较开始ICI前30天内使用抗生素(ATB)与未使用者的疗效。RCC患者中ATB与更高原发进展率、更短PFS和OS相关;NSCLC患者中ATB与更短PFS和OS相关,但原发进展率无显著差异。结论认为ATB与ICI临床获益降低相关。
要点
- RCC患者ATB组原发进展率75% vs 22%,PFS和OS均显著缩短。
- NSCLC患者ATB组PFS和OS显著缩短,但原发进展率无显著差异。
- 开始ICI前30天内使用抗生素与免疫治疗获益降低相关。
核心结论
- 在晚期RCC和NSCLC患者中,抗生素使用与免疫检查点抑制剂临床获益降低相关。
研究设计与样本
- 研究纳入两家学术机构接受抗PD-L1单药或联合治疗的晚期RCC和NSCLC患者。
- 比较开始ICI前30天内使用抗生素者与未使用者,评估客观缓解、RECIST1.1定义的PFS和OS。
主要发现
- RCC患者ATB vs 无ATB:原发进展75% vs 22%(P<0.01),中位PFS 1.9 vs 7.4个月(HR 3.1,95%CI 1.4-6.9,P<0.01),中位OS 17.3 vs 30.6个月(HR 3.5,95%CI 1.1-10.8,P=0.03)。
- NSCLC患者ATB vs 无ATB:原发进展52% vs 43%(P=0.26),中位PFS 1.9 vs 3.8个月(HR 1.5,95%CI 1.0-2.2,P=0.03),中位OS 7.9 vs 24.6个月(HR 4.4,95%CI 2.6-7.7,P<0.01)。
- 多因素分析中,ATB对RCC的PFS和对NSCLC的OS影响仍显著。
临床怎么用
- 对接受ICI的晚期RCC和NSCLC患者,应关注开始治疗前30天内抗生素使用史。
- 需权衡抗生素使用与ICI疗效降低的风险,避免不必要的抗生素暴露。
局限性
- 研究为回顾性设计,样本来自两家学术机构。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The composition of gut microbiota affects antitumor immune responses, preclinical and clinical outcome following immune checkpoint inhibitors (ICI) in cancer. Antibiotics (ATB) alter gut microbiota diversity and composition leading to dysbiosis, which may affect effectiveness of ICI. PATIENTS AND METHODS: We examined patients with advanced renal cell carcinoma (RCC) and non-small-cell lung cancer (NSCLC) treated with anti-programmed cell death ligand-1 mAb monotherapy or combination at two academic institutions. Those receiving ATB within 30 days of beginning ICI were compared with those who did not. Objective response, progression-free survival (PFS) determined by RECIST1.1 and overall survival (OS) were assessed. RESULTS: Sixteen of 121 (13%) RCC patients and 48 of 239 (20%) NSCLC patients received ATB. The most common ATB were β-lactam or quinolones for pneumonia or urinary tract infections. In RCC patients, ATB compared with no ATB was associated with increased risk of primary progressive disease (PD) (75% versus 22%, P < 0.01), shorter PFS [median 1.9 versus 7.4 months, hazard ratio (HR) 3.1, 95% confidence interval (CI) 1.4-6.9, P < 0.01], and shorter OS (median 17.3 versus 30.6 months, HR 3.5, 95% CI 1.1-10.8, P = 0.03). In NSCLC patients, ATB was associated with similar rates of primary PD (52% versus 43%, P = 0.26) but decreased PFS (median 1.9 versus 3.8 months, HR 1.5, 95% CI 1.0-2.2, P = 0.03) and OS (median 7.9 versus 24.6 months, HR 4.4, 95% CI 2.6-7.7, P < 0.01). In multivariate analyses, the impact of ATB remained significant for PFS in RCC and for OS in NSCLC. CONCLUSION: ATB were associated with reduced clinical benefit from ICI in RCC and NSCLC. Modulatation of ATB-related dysbiosis and gut microbiota composition may be a strategy to improve clinical outcomes with ICI.
引用
- Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018. PMID: 29617710. doi:10.1093/annonc/mdy103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。